Collected data revealed that an OV equipped with CD3 × CD20 TCE was more effective against tumor cells than a control OV armed with an irrelevant TCE (CD3 × carcinoembryonic antigen (CEA)) or TCE alone. The gene discussed is CEACAM5; the disease is neoplasm.